Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prov...

Descripción completa

Detalles Bibliográficos
Autores principales: Irani, Malcolm, Fan, Christopher, Glassner, Kerri, Abraham, Bincy P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007976/
https://www.ncbi.nlm.nih.gov/pubmed/36915649
http://dx.doi.org/10.2147/CEG.S367086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007976/
https://www.ncbi.nlm.nih.gov/pubmed/36915649
http://dx.doi.org/10.2147/CEG.S367086

Ejemplares similares